Drug Approval

Blog Post

FDA Approves argenx’s Vyvgart for Treatment of gMG

By Sujatha Gurunathan | December 20, 2021
Featured Article

Demystifying Drug Prices

By Larry Luxner | November 19, 2021
Blog Post

FDA Approves Sanofi Genzyme’s Nexviazyme for Treatment of Pompe Disease

By MDA Staff | August 6, 2021
Blog Post

FDA approves Octapharma’s Octagam® 10% for Treatment of Adults with Dermatomyositis

By Sujatha Gurunathan | July 29, 2021
Blog Post

Biogen’s Early Access Program for Tofersen is Now Open for Individuals with Rapidly Progressing SOD1-ALS

By Sujatha Gurunathan | July 6, 2021
Blog Post

FDA Approves Sarepta Therapeutics’ Amondys 45 for Treatment of DMD Amenable to Skipping Exon 45

By Sujatha Gurunathan | February 25, 2021
Blog Post

How Expedited Drug Approval Impacts the Neuromuscular Disease Treatment Landscape

By Sujatha Gurunathan | February 4, 2021
Blog Post

MDA’s 2021 Advocacy Plan

By Mark Fisher | February 2, 2021
Blog Post

Once a Wild Idea, Successful First-Generation Exon-Skipping Therapies Pave the Way for Personalized Treatments

By Sujatha Gurunathan | November 17, 2020
Blog Post

FDA Approves NS Pharma’s Viltepso for Treatment of DMD Amenable to Exon 53 Skipping

By MDA Staff | August 12, 2020